Human Trials

Boehringer Ingelheim advances first pan-KRAS inhibitor BI 1701963 into clinical testing

Boehringer Ingelheim today presented promising preclinical data from its pan-KRAS program including the novel, oral inhibitor BI 1701963 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, USA.

Femtogenix presents data on antibody drug conjugates containing reduced potency payloads in solid tumour models

Femtogenix, a UK biotechnology company developing the next generation of DNA-interactive Antibody Drug Conjugate (ADC) payloads, announced data demonstrating the potent efficacy and favourable toxicity profile of a reduced potency analogue from its Pyridinobenzodiazepine (PDD) ADC payload platform in solid tumour models.

Imfinzi and Imfinzi plus tremelimumab delayed disease progression in POSEIDON trial

AstraZeneca announced positive progression-free survival (PFS) results for Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody, when added to chemotherapy, from the Phase III POSEIDON trial in previously-untreated Stage IV (metastatic) non-small cell lung cancer (NSCLC).

MacroGenics announces initiation of phase 2/3 MAHOGANY study of margetuximab in gastric or gastroesophageal junction cancer

MacroGenics announced that the first patient has been dosed in the Phase 2/3 MAHOGANY clinical trial of margetuximab, an investigational, Fc-optimized monoclonal antibody targeting HER2, in combination with a checkpoint inhibitor, with or without chemotherapy, as a potential first-line treatment for patients with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.

LIPAC Oncology announces successful completion of phase 1 bladder cancer clinical study and initiation of phase 2A study

LIPAC Oncology LLC today announced the successful completion of a Phase 1 clinical study and progress in a Phase 2A study to further investigate TBC-1002 for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).

RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193

RAPT Therapeutics reported the initiation of its first-in-human Phase 1 clinical trial for RPT193, an orally-administered small molecule CCR4 antagonist that is designed to selectively inhibit the migration of type 2 T helper cells, or Th2 cells, into allergically-inflamed tissues.

Talaris Therapeutics initiates phase 3 clinical trial of FCR001 in living donor kidney transplant recipients

Talaris Therapeutics, a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, announced the initiation of FREEDOM-1, the company’s Phase 3 clinical trial of FCR001 in living donor kidney transplant (LDKT) recipients.

Cyclo Therapeutics completes enrollment in phase 1 trial to evaluate Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C

Cyclo Therapeutics, formerly CTD Holdings, a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced that it has completed patient enrollment in its Phase I trial to evaluate the safety and tolerability of Trappsol Cyclo administered intravenously to Niemann-Pick Disease Type C (NPC) patients.

Odonate Therapeutics announces completion of enrollment in CONTESSA metastatic breast cancer trial

Odonate Therapeutics, a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the completion of enrollment in CONTESSA, a multinational, multicenter, randomized, Phase 3 study investigating tesetaxel as a potential treatment for patients with HER2 negative, hormone receptor positive metastatic breast cancer.